Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Resumo original em inglês

O que aconteceu

Bispecific antibodies emerged as a new class of treatment for patients with relapsed/refractory multiple myeloma. Education on the practicalities of delivery and patient management is vital to optimize outcomes with these novel agents.

A group of 5 experienced hematologists from centers in the United States, Europe and Latin America met to discuss key considerations for bispecific antibody therapy and agree on best practice advice.

O que encontraram

This paper presents advice for best practice at each stage of the bispecific antibody therapy patient journey: patient eligibility, pretreatment medication, step-up dosing, treatment, management of adverse events and long-term care.

Por que isso importa

We believe that the expert insights presented here will help to educate healthcare professionals and optimize patient outcomes by guiding the implementation of bispecific antibody therapy into real-world practice.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.